Shopping Cart 0
Cart Subtotal
USD 0

KOL Perceptions of Ustekinumab Data Presented at ACR 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

KOL Perceptions of Ustekinumab Data Presented at ACR 2017

Summary

This KOL Insight briefing focuses on perceptions of Ustekinumab Data Presented at ACR 2017.

The briefing includes analysis of KOL opinion on the following topic areas-

- Perception of ustekinumab's Phase II efficacy data in SLE

- Views on ustekinumab demonstrating significant efficacy at Week 24 in SLE

- Ustekinumab's Phase II CLASI data in SLE

- Ustekinumab's Phase II safety data in SLE

- Impact of ustekinumab data in other indications on opinion of ustekinumab in SLE

- Endpoints used in the Phase II ustekinumab trial in SLE

- Anticipated future use of ustekinumab in SLE

- Ideal additional endpoints or data for future ustekinumab trials in lupus

Key Highlights

- Most KOLs had a positive opinion of ustekinumab's efficacy in SLE and highlighted that it appears to have a better response rate vs. belimumab

- KOLs were broadly impressed with ustekinumab's CLASI data, and expect it to encourage ustekinumab uptake in lupus skin manifestations

- Most KOLs had a positive view of ustekinumab's safety, but concerns were raised regarding the small patient population in the Phase II trial.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our lupus key opinion leaders (KOLs)

- In total, we conducted interviews with 14 KOLs: Seven Europe-based & seven US-based

- Interviews performed in December 2017.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Ustekinumab Data Presented at ACR 2017"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Ustekinumab, lupus, ACR


Companies

Janssen